Manifesto on inhaled triple therapy in asthma: an Interasma (Global Asthma Association – GAA) document. (10th November 2022)

• Record Type: Journal Article
• Authors: Braido, Fulvio; Tiotiu, Angelica; Guidos-Fogelbach, Guillermo; Baiardini, Ilaria; Cosini, Filippo; Correia de Sousa, Jaime; Bikov, Andras; Novakova, Sylvia; Labor, Marina; Kaidashev, Igor; Nedeva, Denislava; Kowal, Krzysztof; Mihaicuta, Stefan; Urrutia Pereira, Marilyn; Solé, Dirceu; Novakova, Plamela; Chong-Neto, Herberto; Vrzy, Laura; Ansotegui, Ignacio J.; Bernstein, Jonathan A.; Boulet, Louis-Philippe; Canonica, Giorgio Walter; Dubuske, Lawrence; Nunes, Carlos; Ivancevich, Juan Carlos; Santus, Pierachille; Rosario, Nelson; Emelyanov, Alexander; Steiropoulos, Paschalis
• Is Part Of: Journal of asthma. Volume 59:Number 12(2022)
• Page Start: 2402
• Page End: 2412
• Publication Date: 2022-11-10
• Subjects: Asthma management -- asthma control -- asthma pharmacotherapy -- asthma treatment -- manifesto -- Interasma -- consensus; Asthma -- Periodicals; 616.238005
• DOI: 10.1080/02770903.2021.2022160
• Languages: English
• ISSNs: 0277-0903

Abstract

Abstract: Objective: The optimal use of drug combinations for the management of asthma is providing significant results. This has prompted Interasma (Global Asthma Association) to take a position on inhaled triple therapy in asthma.Methods: We performed an extensive literature research to clinical trials, meta-analyses, randomized controlled trials and systematic reviews.Results: Starting from an extensive literature review, Interasma executive committee discussed and approved this Manifesto, developed by Interasma scientific network (INES) members.Conclusions: The manifesto describes the evidence gathered to date and states, advocates, and proposes issues on inhaled corticosteroid (ICS) plus long-acting beta 2 agonist (LABA) and long-acting muscarinic antagonists (LAMA) with the aim of challenging assumptions, fostering commitment, and bringing about change.